Abstract: The present invention relates to improved compounds for use in the treatment of diseases or conditions where the removal of senescent cells, scarred cells, and/or cancerous cells is beneficial, for example cancer. The invention also relates to methods of treating an individual suffering, or suspected of suffering, from a disease or condition wherein the removal of senescent cells, scarred cells, and/or cancerous cells is beneficial.

Abstract: The present invention provides, among other things, improved methods and pharmaceutical compositions for treating cystic fibrosis based on codon optimized mRNA encoding an engineered or mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein.

Abstract: The invention relates to a protein for use in diagnosing and treating primary or secondary sclerosing diseases, a fusion protein, and nucleotide sequence and a vector, and to a pharmaceutical composition for use in diagnosing and treating primary or secondary sclerosing diseases.

Abstract: The use of Fc-tagged Pregnancy-specific glycoprotein 1 (PSG1-Fc) in a method of treatment of osteoarthritis or damaged cartilage in a human, in which the PSG1 is administered by intra-articular injection, is described. Also described is the use of CC49 in a method of treatment of osteoarthritis or damaged cartilage in an equine mammal, in which the CC49 is administered by intra-articular injection. (FIG. 3A-C) Also described is the use of PSG1 in a method of treatment of wounds, scarring, burns and diabetic ulcers in a mammal.

Abstract: Milk fat globule-epidermal growth factor—factor VIII (MFG-E8) derived oligopeptides and pharmaceutical compositions containing the oligopeptides are provided for treating sepsis and inflammatory conditions.

Abstract: The present invention relates to methods of treating neuropathic corneal pain (NCP) comprising administration of nerve growth factor (NGF).

Abstract: Interferon-?-inducible protein 10 (IP-10) peptides, IP-10 peptide variants and in silico designed C-X-C chemokine receptor 3 (CXCR3) peptide agonists are described. The small peptides can be used for inhibiting pathological tissue remodeling and treating fibrosis in a subject, such as a subject with fibrosis of the heart, lung, liver, kidney or skin. The peptide agonists can also be used to treat cardiovascular disease, including myocardial infarction and ischemia-reperfusion injury. Also described are in silico designed peptide antagonists that bind CXCR3 or ligands of CXCR3. These antagonist peptides block CXCR3 signaling by disrupting interaction of CXCR3 with its ligand. Antagonist peptides can be used, for example, to treat myocarditis and atherosclerosis. In additional embodiments agonists and antagonists of CXCR4 are disclosed.

Abstract: The subject invention pertains to novel methods of treatment for subjects suffering from anemia, particularly as a result of erythropoiesis-stimulating agents (ESAs) resistant anemia. The methods comprise administering at least two compositions to a subject, in which the compositions can comprise a first composition comprising an ESA and a second composition comprising a thrombopoietin receptor agonist (TPO-RA). The combination of ESA with TPO-RA can stimulate the expansion of hematopoietic stem cells.

Abstract: This document relates to methods and materials involved in treating stroke. For example, nanoparticles (e.g., polymer-coated nanoparticles) designed to deliver two or more poly peptides that are normally secreted from mesenchymal stem cells (MSCs; e.g., MSCs of a human less than 33 years of age)) to the brain are provided as well as methods for using such nanoparticles to treat a mammal (e.g., a human) having or having had a stroke.

Abstract: Disclosed are an OXM3 storage agent, an OXM3 formulation and a preparation method. The OXM3 storage agent comprises 0.5-5 mg/mL tromethamine, 0.1-100 mg/mL stabilizer, 0.01-5 mg/mL chelating agent and a solvent, wherein: the stabilizer comprises one or more of mannitol, propylene glycol, arginine, arginine hydrochloride, histidine and histidine hydrochloride, the chelating agent comprises edetate disodium, and the solvent comprises water. The OXM3 formulation prepared from the OXM3 storage agent can ensure that the active ingredient OXM3 is stably stored for at least 6 months, preferably for 12 months or more, and more preferably for 18-24 months or more.

Abstract: Provided are a glucagon derivative and use thereof. The pharmaceutical composition contains a glucagon derivative and a pharmaceutically acceptable excipient, wherein the glucagon derivative is a peptide including an amino acid sequence of the following General Formula 1: X1-X2-QGTF-X7-SD-X10-S-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-F-X23-X24-W-L-X27-X28-X29-X30 (General Formula 1, SEQ ID NO: 46). A method for treating chronic renal disease is also disclosed.

Abstract: The present invention relates to methods of using dulaglutide for the treatment of chronic kidney disease in patients having moderate to late stage chronic kidney disease.

Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.

Abstract: Provided herein are compositions, methods, kits, and viral particles for treating a disease or disorder associated with a deep intronic mutation using an engineered, non-naturally occurring Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)—CRISPR associated (Cas) (CRISPR-Cas) system. In some aspects, provided herein is a self-limiting CRISPER-Cas system.

Abstract: The present invention provides an mRNA nanocapsule and use thereof, comprising a virus-like particle (VLP) formed by self-assembly of a plurality of capsid proteins (CPs), an mRNA encoding Cas13 protein, and a guide RNA. The mRNA includes a capsid protein binding tag to be encapsidated in the VLP so that the mRNA can stably enter cells and the Cas13 protein can be translated.

Abstract: Provided herein are methods of treating Pompe disease comprising administering a population of recombinant human acid a-glucosidase molecules or a pharmaceutical composition or formulation thereof, and a pharmacological chaperone.

Abstract: Disclosed are compositions, methods, uses, kits and articles of manufacture, which are based on the use of a hyaluronidase and a collagen-reducing agent, for reducing or inhibiting the development of fibrosis in a tissue, or for treating collagen-mediated disorders. In specific embodiments, the collagen-mediated disorders are fibroproliferative disorders involving alterations of collagen, including fibromatoses such as Dupuytren's disease. Peyronie's disease and Ledderhose's disease.

Abstract: Provided herein are stable, aqueous, non-lyophilized formulations of L-asparaginase. Also provided herein are methods of using such formulations in the treatment of one or more diseases, disorders, or conditions (for example, cancers such as Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)) that are treatable by asparagine depletion.

Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

Abstract: The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme. In another aspect, the recombinant bacterial cells further comprise at least one heterologous gene encoding an importer of oxalate. The invention further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders in which oxalate is detrimental, such as hyperoxaluria, using the pharmaceutical compositions of the invention.

Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.

Abstract: This disclosure describes, in one aspect, immunogens effective for treating and/or diagnosing tauopathy, and immunotherapeutic compositions and methods involving those immunogens. Generally, the immunogen includes an antigen presentation component and a microtubule-associated tau protein (MAPT) component linked to at least a portion of the antigen presentation component. This disclosure describes, in another aspect, a transgenic mouse. Generally, the transgenic mouse possesses brain cells that have a polynucleotide that encodes human microtubule-associated protein tau (MAPT). The polynucleotide further exhibits a deletion of at least a portion of endogenous mouse MAPT. The transgenic mouse also includes a forebrain neuron-specific deletion of a polynucleotide that encodes Myeloid Differentiation Primary Response Gene 88 (MyD88). In a further aspect, this disclosure describes a method of producing the transgenic mouse.

Abstract: The present disclosure provides antigen presenting polypeptide comprising a TGF-? MOD that is reversibly masked and acts as a TGF-? receptor agonist. The antigen presenting polypeptides comprising one or more chemical conjugation sites for incorporation of, for example, Type 1 Diabetes (T1D) associated epitope containing polypeptides. The antigen-presenting polypeptides and their T1D-associated epitope conjugates are useful for modulating the activity of a T-cell, and accordingly, the present disclosure provides methods of modulating activity of a T-cell in vitro and in vivo as a method of treatment of T1D.

Abstract: The present invention discloses a recombinant protein capable of resisting multiple sclerosis and a preparation method and application thereof, and belongs to the technical field of biopharmacy. The recombinant protein of the present invention comprises Mycobacterium tuberculosis heat shock protein 65 and 6-segment tandem repeat myelin oligodendroglia glycoprotein antigen epitope polypeptides with multiple sclerosis autoimmune antigen characteristics at the 33rd-55th sites. The recombinant protein capable of resisting multiple sclerosis is used for preparing multiple sclerosis vaccines and/or preparing multiple sclerosis drugs. The present invention can play a role in preventing multiple sclerosis and can avoid side effects caused by most of disease modifying therapy (DMT) drugs.

Abstract: The gist of the invention consists in the therapeutic vaccine for treatment of diabetes type 1 in children, which contains Treg cells CD3(+)CD4(+)CD25(high)CD127(?). Claimed too is the cell sorter used to produce the vaccine and the method of multiplying Treg cells in vitro.

Abstract: An immunogenic composition is provided herein. The immunogenic compositions are used to identify and select immunogenic antigens that elicit immune responses in a subject and may be subsequently used in multi-antigen vaccine compositions against one or more diseases or conditions. According to some embodiments, the immunogenic composition may include a plurality of nucleic acid fragments or minigenes derived from a nucleic acid library, wherein each nucleic acid fragment encodes a different antigen or functional portion thereof, and wherein the different antigens or functional portions thereof are associated with one or more disease or condition. The immunogenic composition may also include a delivery medium loaded with the plurality of nucleic acid fragments and in some embodiments, the delivery medium is loaded with nucleic acid fragments in such a way that individual antigen presenting cells receive only a subset of the nucleic acids within a vaccine in order to minimize antigenic competition.

Abstract: Provided are modified bacteria and methods of using the modified bacteria for prophylaxis or treatment of bacterial infections. The modified bacteria contain one or more genomic modifications such that the genomes of the bacteria are altered to encode and produce a holin protein and to encode and produce a lysozyme. The modified bacteria are illustrated using a type of Salmonella enterica (SE) in the form of autolytic SE serovar Typhimurium (S. typhimurium).

Abstract: The present invention pertains to a vaccine comprising in combination an IgM protease antigen of Streptococcus suis and a Streptococcus suis bacterin of serotype (9), sequence type (16), for use in a method for protecting pigs against a pathogenic infection with Streptococcus suis serotype (9), sequence type (16).

Abstract: The present invention relates to the fields of sexually transmitted disease and immunology. More specifically, but not exclusively, the invention provides a composition and methods to prepare and administer a vaccine for Neisseria gonorrhoede and/or other gram-negative bacteria such as by using psoralen-inactivated bacteria.

Abstract: Compositions and methods for eliciting an immune response in a subject against Vibrio cholerae are provided. The compositions include fusion proteins with one or more epitopes from Vibrio cholerae, nucleic acids and vectors encoding the fusion proteins, pharmaceutical compositions, immunogenic compositions, and vaccines. In examples, the methods include administering a disclosed composition to a subject, such as a human.

Abstract: This invention provides in general, a composition suitable for use in inducing anti-HIV-1 antibodies, such as immunogenic compositions comprising envelope proteins and nucleic acids to induce cross-reactive neutralizing antibodies and increase their breadth of coverage. The invention also provides methods of inducing such broadly neutralizing anti-HIV-1 antibodies using such compositions.

Abstract: Compositions for prevention of Foot and Mouth Disease (FMD) are provided, comprising an antigen component in the amount equivalent to 0.5-20 ?g FMD virus and an adjuvant component comprising oil, an immunostimulatory oligonucleotide, and a polycationic carrier. Methods of using the composition, as well as the methods of reducing FMD persistence are also provided.

Abstract: Disclosed herein is an immunogenic composition for enhancing immunogenicity and treatment efficacy. The immunogenic composition comprises a nanoparticle (e.g., a nanodiamond) and an immunogenic conjugate having formula (I): X-L-Y, wherein X is an agonist module, L is a linker unit, and Y is an antigen. In the immunogenic composition, the immunogenic conjugate is coupled to the outer surface of the nanoparticle. Also encompasses herein is a method of preventing or treating a disease in a subject in need thereof, comprising administering an effective amount of the immunogenic composition set forth above to the subject.

Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

Abstract: Embodiments of immunogens comprising a multimer of NiV G ectodomains and protein nanoparticles comprising an NiV G ectodomain are provided. Also disclosed are nucleic acids encoding the immunogens and methods of their production. Methods for inducing an immune response in a subject by administering a disclosed immunogen to the subject are also provided. In some embodiments, the immune response treats or inhibits NiV infection in a subject.

Abstract: The present invention relates to stabilized pre-fusion human parainfluenza virus 3 (HPIV3) F protein, and fragments thereof. The invention also relates to nucleic acid molecules encoding such proteins and fragments, and to the use of the proteins, fragments and nucleic acid molecules.

Abstract: The technology described herein is directed to compositions and methods for modifying and controlling the activity of cells by expression of proteins from self-amplifying RNA (saRNA). Also described herein are compositions and methods for modifying and controlling the activity of cells by expression of proteins from self-amplifying RNA that is substituted with chemically modified nucleotides.

Abstract: Recombinant chimeric bovine/human parainfluenza virus 3 (rB/HPIV3) vectors expressing a recombinant Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike (S) protein as well as methods of their use and manufacture, are provided. The rB/HPIV3 vector comprises a genome comprising a heterologous gene encoding the recombinant SARS-COV-2 S protein. Nucleic acid molecules comprising the sequence of the genome or antigenome of the disclosed rB/HPIV3 vectors are also provided. The disclosed rB/HPIV3 vectors can be used, for example, to induce an immune response to SARS-COV-2 and HPIV3 in a subject.

Abstract: The present invention relates to immunogenic compositions and methods for immunization against variants of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein derived from Beta (B.1.351) variant and methods using an immunogenic composition derived from SARS-COV-2 Beta (B.1.351) variant.

Abstract: Provided is a liquid formulation of a six combined vaccine containing DPT-IPV-Hib-HBs, in which a HBs antigen is stably adsorbed and retained to an aluminum adjuvant, and PRP as a Hib antigen is stably coupled and retained to a carrier protein.

Abstract: The present invention is directed to a method for increasing immunization efficiency of a subject to a pathogen, including administering a therapeutically effective amount of a pharmaceutical composition including: (a) a heat labile toxin subunit B (LTB) polypeptide or a functional analog thereof, and (b) an immunogenic polypeptide derived from the pathogen.

Abstract: The present invention provides immunogenic chimeric respiratory syncytial virus (RSV)-parainfluenza virus type 3 (PIV3) compounds and associated compositions, along with methods of treating, preventing and/or diagnosing RSV- and PIV3-related disorders.

Abstract: The present disclosure relates, in general to methods of treating peanut allergy using nanoparticles encapsulating peanut antigens to induce antigen-specific tolerance.

Abstract: The present invention provides methods for modulating antigen-specific antibody responses by administering to a mammal a compound that selectively either activates or inhibits a specific subset of sensory neurons that express TRPV1.

Abstract: An immunogenic composition containing at least one antigen and at least one adjuvant including at least one Metal-Organic Framework including an inorganic part based on aluminum and an organic part based on polydentate ligand chosen from fumarate, muconate, mesaconate, oxalate, oxaloacetate, succinate, malate, citrate, aconitate, isophthalate, substituted isophthalate, 2,5-thiophenedicarboxylate, 2,5-furandicarboxylate, trimesate, trimellitate and pyromellitate, the antigen being immobilized at least within the Metal-Organic Framework.

Abstract: The present disclosure relates to lysophosphatidylcholine (LPC) compounds and uses thereof in hyperactivating mammalian dendritic cells, such as human dendritic cells or canine dendritic cells. The present disclosure also relates to compositions comprising a LPC and one or more of a pathogen recognition receptor agonist, an antigen, and mammalian dendritic cells, as well as methods for production and use of the compositions.

Abstract: The present invention provides methods for treating patients suffering from refractory hypercholesterolemia. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to ANGPTL3 in combination with a therapeutically effective amount of a statin, a first lipid lowering agent other than a statin, and a second lipid lowering agent other than a statin.

Abstract: Provided are methods, compositions, uses and articles of manufacture of combination therapies involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and the use of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a non-Hodgkin lymphoma (NHL), such as relapsed or refractory NHL or specific NHL subtype.

Abstract: Provided herein are novel compositions enriched in gdT cells with high therapeutic potential. Methods to produce such compositions and methods of uses thereof in adoptive immunotherapies are also provided.

Abstract: Provided are modified tumor-infiltrating lymphocyte and the use thereof, in particular provided is a method for culturing the tumor-infiltrating lymphocyte (TIL), which comprises increasing the expression and/or enhancing the activity of at least one cytokine of the TIL. Also provided is a method for preventing and/or treating tumors by using the tumor-infiltrating lymphocyte.